« Back
Home /
LPAR4 Antibody

LPAR4 Antibody

Manufacturer	Cusabio
Category	Metabolism Diabetes Glucose Homeostasis Antibodies Obesity Immunohistochemistry Western Blot ELISA Immunofluorescence Primary Antibodies
Type	Antibody Polyclonal
Specific against	Human, Mouse
Isotype	IgG
Format	Liquid
Applications	WB, IF, IHC, ELISA
Amount	50ug
Host	Rabbit
Item no.	CSB-PA013050LA01HU-50ug
Targets	GPR119
eClass 6.1	32160702
eClass 9.0	32160702
Available
Immunogen Species	Human
UniprotID	Q99677
Immunogen	Recombinant Human Lysophosphatidic acid receptor 4 protein (1-43AA)
Applications info	ELISA, WB, IHC, IF, Recommended dilution: WB:1:1000-1:5000, IHC:1:200-1:500, IF:1:50-1:200
Dilution ratio 1	ELISA:1:2000-1:10000
Dilution ratio 2	WB:1:1000-1:5000
Dilution ratio 3	IHC:1:200-1:500
Dilution ratio 4	IF:1:50-1:200
Background	Receptor for lysophosphatidic acid (LPA), a mediator of diverse cellular activities. Transduces a signal by increasing the intracellular calcium ions and by stimulating adenylyl cyclase activity. The rank order of potency for agonists of this receptor is 1-oleoyl- > 1-stearoyl- > 1-palmitoyl- > 1-myristoyl- > 1-alkyl- > 1-alkenyl-LPA.
Conjugate	Non-conjugated
Buffer	Preservative: 0.03% Proclin 300 Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Storage	Upon receipt, store at -20C or -80C. Avoid repeated freeze.
Purification Method	>95%, Protein G purified
General Research Areas	Neuroscience
Initial Research Areas	Neuroscience

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CSB-PA013050LA01HU-50ug-datasheet.pdf

Request safety datasheet

Simple Order Order Subscription

Amount: 50ug

available

Delivery expected until 5/30/2024